| Study Name | Description Sort descending | Trial Category | Trial SubCategory |
|---|---|---|---|
| Portico NG | This is a study of an updated Portico Valve for TAVR. | Heart & Vascular | Structural Heart Disease |
| Destiny 614 | This is an open-label, multi-center, long-term study of patients with genetically-confirmed Prader-Willi Syndrome (PWS). | Endocrinology | Pediatrics |
| Amplitude | This research study is a way to find out if the Study Drug is safe and if it works to help people with APOL-1 mediated Chronic Kidney Disease. | Nephrology | Proteinuric Kidney Disease |
| PPP/PAN/PSR | This study is a registry study. The purpose is to collect information over time about how Medtronic products are working and/or the outcome of the treatment. The registry will be used to support post-market surveillance activities and post-approval studies (e.g., to collect safety and performance information). In addition, it will be used to obtain clinical evidence for the development and improvement of medical devices, therapies, device guidelines, patient services/solutions and provide clinical data to support health economics and clinical outcomes research. The registry is not an experimental clinical study. | Heart & Vascular | Cardiac Arrhythmia |
| NRG-LU007 | This study is comparing effectiveness of atezolizumab alone vs atezolizumab and radiation. You must be diagnosed with extensive stage small cell lung cancer. | Cancer | Small Cell Lung |
| EA3161 | This study is comparing maintenance Nivolumab vs observation in patients with locally advance, intermediate risk HPV Positive oropharynx cancer. | Cancer | Oropharyngeal |
| EA5182 | This study is comparing Osimertinib and Bevacizumab vs Osimertinib alone as first-line treatment for patients with metastatic EGFR mutant Non-Small Cell Lung Cancer (NSCLC). You must be diagnosed with stage 3 or 4 NSCLC. | Cancer | Non-Small Cell Lung |
| EA3132 | This study is comparing radiation therapy with and without Cisplatin. You must have surgically resected squamous cell carcinoma of the head and neck stage 3 or 4. | Cancer | Head and Neck |
| S2302 | This study is comparing Ramucirumab + Pembrolizumab vs standard of care chemo for patients previously treated with immunotherapy. You must be diagnosed with stage 4 or recurrent Non-Small Cell Lung Cancer (NSCLC). | Cancer | Metastatic Non-Small Cell Lung |
| S1914 | This study is comparing the use of Atezolizumab + SBRT (stereotactic body radiation therapy) vs SBRT Alone in high risk early stage non-small cell lung cancer (NSCLC). You must be diagnosed with stage 1 or 2 non-small cell lung cancer (NSCLC). | Cancer | Non-Small Cell Lung |
| S2209 | This study is for frail-intermediately fit newly diagnosed multiple myeloma patients. Your current lab values will be used to determine if you qualify for this study. This study compares different chemo regimens to determine the effectiveness of them. | Cancer | Multiple Myeloma |
| EAY191-N5 | This study is for patient's who have HER2+ gynecologic cancers or other solid tumors. Cannot have breast cancer. You must have recurrent disease or progressed on treatment. | Cancer | Her2+ Solid Tumors |
| EAY191-E5 | This study is for patients who have a KRAS G12C mutation and advanced/metastatic solid tumors. Your cancer must have progressed on standard of care therapy. You cannot have colorectal cancer or non-small cell lung cancer. | Cancer | Solid Tumors |
| S1608 | This study is for patients who have failed to achieve a complete remission or have relapsed within 2 years after completing treatment. You must have been diagnosed with follicular lymphoma grade 1, 2, or 3. | Cancer | Follicular Lymphoma |
| EA8211 | This study is for patients with renal cell cancer who have a total of 2-5 metastatic lesions. The study is looking at using radiation to the metastatic sites in combination with chemotherapy. | Cancer | Metastatic Renal Cell |
| S2101 | This study is for patients with Stage III or IV, unresectable, recurrent, or metastatic melanoma. This study uses Nivolumab and Cabozantinib to treat patients. | Cancer | Melanoma |
| EAY191-N2 ComboMATCH | This study is for people diagnosed with hormone receptor positive breast cancer that has spread. A NF1 gene mutation must exist. | Cancer | Metastatic Breast |
| S1703 | This study is looking at overall survival or patients monitored with serum tumor markers veruss usual care. You must be diagnosed with metastatic hormone receptor positive breast cancer. | Cancer | Metastatic Breast |
| A221805 | This study is looking at using Duloxetine to prevent Oxaliplatin induced peripheral neuropathy. You must be diagnosed with stage 2 or 3 colorectal cancer scheduled to receive chemo with oxaliplatin. | Cancer | Colorectal |
| S1706 | This study is looking at using Olaparib after a masectomy at the same time as radiation vs getting radiation alone to determine if adding the medication provides better results. | Cancer | Breast |
| ISPY 2 | This study uses the type of breast cancer you are diagnosed with to determine what treatment you are given. You must be diagnosed with stage 2 or stage 3 breast cancer. This study requires regular MRI's. | Cancer | Breast |
| Arrhythmia Detection After Myocardial Infarction (AID-MI) | This study will evaluate the use of an insertable cardiac monitor in patients following an acute myocardial infarction (heart attack) to determine if cardiac monitoring results in more rhythm-related findings that change management compared to standard of care post heart attack management in patients who do not receive the insertable cardiac monitor. | Heart & Vascular | Cardiac Arrhythmia |
| COG-AHEP0731 | Treatment of Children with All Stages of Hepatoblastoma | Childhood Cancers | Blastoma |
| AALL0932 | Treatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) | Childhood Cancers | Leukemia |
| ANBL1232 | Utilizing Response-and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High Risk Neuroblastoma | Childhood Cancers | Blastoma |
Unsupported Browser! This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.